Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Chief Medical Officer | October 09, 2024 | October 10, 2024 |
| Jaguar Health, Inc.JAGX · Entity 8387 | Chief Scientific Officer | December 19, 2016 | December 21, 2016 |
| Molecular Templates, Inc.MTEM · Entity 85987 | See remarks | February 15, 2023 | February 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Indaptus Therapeutics, Inc.
Report date October 09, 2024 · Filed October 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2034-10-09 | Direct | 75,000 |
Reported balance
After 2024-10-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-10-09 · Grant · Acquired 75,000 · Balance 75,000 F1: The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Jaguar Health, Inc.
Report date December 19, 2016 · Filed December 21, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2026-12-19 | Direct | 2,866 |
Reported balance
After 2016-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-12-19 · Grant · Acquired 2,866 · Balance 2,866 F1: Granted pursuant to the Issuer's 2014 Equity Incentive Plan. F2: Vests in equal monthly installments, beginning on January 19, 2017, such that it is vested in full on the 3-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Issuer's 2014 Equity Incentive Plan.
F2: Vests in equal monthly installments, beginning on January 19, 2017, such that it is vested in full on the 3-year anniversary of the grant date.
Molecular Templates, Inc.
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2033-02-14 | Direct | 170,000 |
Reported balance
After 2023-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 170,000 · Balance 170,000 F1: 25% of the shares subject to the option shall vest on February 15, 2024, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option shall vest on February 15, 2024, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2024 Filed Oct 10, 2024 16:05 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001493152-24-040728 · ownership.xml · derivative · entry 1 Waltzman Roger J. · CIK 0001678987 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-10-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 16:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-24-003449 · ownership.xml · derivative · entry 1 Waltzman Roger J. · CIK 0001678987 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-01-22 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on January 22, 2025 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 22, 2027. Read SEC document |
| August 07, 2023 Filed Aug 7, 2023 17:25 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001493152-23-027061 · ownership.xml · derivative · entry 1 Waltzman Roger J. · CIK 0001678987 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-08-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on August 7, 2024 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on August 7, 2026. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 08:00 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 170,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000899243-23-005364 · doc4.xml · derivative · entry 1 Waltzman Roger J. · CIK 0001678987 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 15, 2024, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 08:07 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0000899243-22-006731 · doc4.xml · derivative · entry 1 Waltzman Roger J. · CIK 0001678987 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 15, 2023, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 17:01 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $14.05 | $0.00 |
DisclosureSEC source: 0000899243-21-006912 · doc4.xml · derivative · entry 1 Waltzman Roger J. · CIK 0001678987 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 15, 2022, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:59 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0000899243-20-004990 · doc4.xml · derivative · entry 1 Waltzman Roger J. · CIK 0001678987 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-02-14 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 14, 2021, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 16:56 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0000899243-19-004401 · doc4.xml · derivative · entry 1 Waltzman Roger J. · CIK 0001678987 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2029-02-19 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 19, 2020, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 19:41 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 2,866 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001104659-16-163180 · a4.xml · derivative · entry 1 Waltzman Roger J. · CIK 0001678987 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,866 Underlying: Common Stock · 2,866 shares Expires 2026-12-19 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan. F2 · derivative.exercise_date: Vests in equal monthly installments, beginning on January 19, 2017, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.